ArticleJournal of orthopaedic surgery and research2025
Optimal timing of bone marrow aspiration concentrate injection for tendon-bone healing in a chronic rat rotator cuff tear model.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe Bone marrow aspirate concentrate (BMAC) injection is a beneficial therapy for bone-tendon interface (BTI) regeneration following rotator cuff (RC) repair. However, the optimal timing for BMAC injection remains undetermined. Injection at different timepoints may influence BTI regeneration.
methodsAfter concentrating bone marrow (BM) to obtain BMAC, the viability of cells, nucleated cell content, platelet count, stem cell number, and concentration of growth factors in both BM and BMAC were comparatively evaluated. Supraspinatus tendon tears were induced at the greater tuberosity in 152 Wistar rats. Three weeks after the tear induction, the rats following RC repair surgery were then randomly divided into four groups based on the timing of BMAC injection: PBS injected immediately during RC repair (PBS group), BMAC injected immediately (P0-BMAC group), on postoperative day 7 (P7-BMAC group), or day 14 (P14-BMAC group). Eight weeks after RC repair, the supraspinatus tendon-proximal humerus complexes were harvested for evaluating BTI regeneration using micro-CT, histological and biomechanical testing. Additionally, at the day 0, 3, 10, 17 after RC repair, the specimens were harvested for evaluating the inflammation and oxidative stress.
resultsCell viability in the BMAC exceeded 90%. The BMAC contained higher concentrations of platelets, nucleated cells, stem cells, TGFβ1, and IGF1 compared to BM. In vivo results demonstrated that the BMAC injection on postoperative day 7 had a more pronounced effect on BTI regeneration compared to other timepoints. Micro-CT analysis revealed that the new bone in the P7-BMAC group formed and remodelled significantly better than in the P14-BMAC, P0-BMAC, or PBS groups. Histologically, the P7-BMAC group exhibited a significantly higher rate of fibrocartilage regeneration at the RC healing site compared to the P14-BMAC, P0-BMAC, or PBS groups. Biomechanically, the P7-BMAC group showed significantly higher failure load and stiffness compared to the P14-BMAC, P0-BMAC, or PBS groups. Moreover, the P7-BMAC group showed significantly inhibiting inflammation and decreasing oxidative stress in the ST-proximal humerus complexes as compared with the other groups.
conclusionsBMAC injected at 7 days postoperatively is an optimal timing of the BMAC Injection for BTI regeneration in a chronic rat RCT model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.